Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors

Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKI) are recommended first-line therapy for advanced non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations. It is of clinical interest to identify concurrent genetic mutations in NSCLC patients with EGFR mutations in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Shih-Chieh, Lai, Yi-Chun, Chang, Cheng-Yu, Huang, Li-Kuo, Chen, Shu-Jen, Tan, Kien Thiam, Yu, Pei-Ning, Lai, Jiun-I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700434/
https://www.ncbi.nlm.nih.gov/pubmed/31401335
http://dx.doi.org/10.1016/j.tranon.2019.07.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700434/
https://www.ncbi.nlm.nih.gov/pubmed/31401335
http://dx.doi.org/10.1016/j.tranon.2019.07.008

Ejemplares similares